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Abstract
Purpose This study aimed to collect confirmatory data in
support of the safety and efficiency of the ArtVentive
EOSTM for the treatment of the pelvic congestion syn-
drome (PCS). This study was based on the OCCLUDE 1
Study Protocol approved by the Local Ethics Committee.
Materials and Methods A prospective study carried out in
June and July 2014 included 12 women aged 21–48 years
(mean 31 years) scheduled for PCS embolization using the
ArtVentive EOSTM. The inclusion criteria were clinical
symptoms of PCS documented by transvaginal Doppler
ultrasound and pelvic MRI. The pelvic pain was assessed
by VAS score from 0 to 10 (0 represents lack of pain and
10 unbearable pain). A decrease in pelvic pain intensity
based on the VAS was considered a clinical success.
Results Successful embolization procedures with ArtVen-
tive EOSTM were performed in 11 out of 12 patients. Nine
patients underwent unilateral embolization of the left
ovarian vein, and two had bilateral embolization of the
ovarian veins. Complete ovarian vein occlusion confirmed
by post deployment venography was achieved in all 11
patients. Procedures lasted from 19 to 45 min (average
28 min). Pain intensity decrease was observed in all 11
patients—a decrease of 5.6 points—from 7.3 pre-procedure
to 1.6 post-embolization (standard deviation: 0.67). In one
case, the left ovarian vein was injured by guide wire
manipulation with contrast extravasation—not clinically
significant.
Conclusions The use of ArtVentive EOSTM for occlusion
of the ovarian veins in PCS patients is safe and effective.
Keywords Pelvic congestion syndrome 
Embolization  Vascular occluder
Introduction
Pelvic congestion syndrome (PCS) is a common cause of
chronic lower abdominal/pelvic pain, estimated to affect
about 10–15 % of women, predominantly between the ages
of 30 and 45 [1]. PCS is anatomically characterized by the
presence of varicose and incompetent parametrial veins [2].
In the majority of patients, PCS manifests with non-cyclic
abdominal or pelvic pain lasting for at least half a year.
Typically, it is characterized by chronic, dull and contin-
uous discomfort, increasing on prolonged standing during
menstruation and after sexual intercourse. Other symptoms
include vulvar swelling, lower limb oedema and urinary
urgency. Women with PCS are typically premenopausal,
and a relationship between PCS and endogenous oestrogen
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levels has been suggested, since oestrogen is known to
weaken vein walls [3–5].
1. In order to evaluate the characteristic set of clinical
symptoms, imaging examinations may be useful to
differentiate the causes of pain. The preferred imaging
study for PCS is transvaginal ultrasound (TVUS) with
Doppler imaging, which enables dynamic visualisation
of the flow in pelvic venous plexus. The unaffected
pelvic veins are relatively straight structures with a
diameter less than 4 mm. In patients with PCS,
ultrasound findings commonly include parametrial
venous plexus dilation above 6 mm and slow or
reversed blood flow during Valsalva manoeuvre.
Important is also to find dilated arcuate veins passing
through the uterine muscle. The possibility of oestro-
gen overstimulation in women with PCS may explain
why more than 50 % also have cystic ovaries as
observed during TVUS [6–8].
Another non-invasive imaging technique to assess the
pelvic venous outflow is the MRI (Fig. 1). Using a routine
FSE T2-weighted sequence with fat saturation is able to
evaluate dilated ovarian veins (Fig. 2a). A volumetric
single slab TSE sequence is very useful which enables
acquisition of high-resolution 3D datasets (i.e. SPACE).
There are also possibly more advanced techniques like
time-resolved MR-angiography, which are used for not
only detecting but also grading ovarian venous reflux.
Unfortunately, all MR techniques are poor in assessing the
possible coexisting internal iliac venous incompetence
[9–11].
Endovascular diagnosis of PCS is based on venography,
which remains highly effective modality. Diagnostic
venography offers a direct imaging of the blood reflux into
varicose plexus. It provides dynamic flow of information
and accurate measurements of the ovarian and internal iliac
veins [11, 12]. Venographic findings in PCS include ret-
rograde flow in dilated ovarian veins and the presence of
tortuous collateral pelvic venous pathways. Delayed
clearance of injected contrast is visible [5, 13].
The treatment of PCS depends mainly on the severity of
the pain. Non-steroid anti-inflammatory drugs are often
used, and contraceptives have a role in cases of pain
associated predominantly with menstruation [14]. Avail-
able studies also describe the use of medroxyprogesterone
which alleviates the symptoms in about 40 % of patients
[1, 14]. Before the advent of interventional radiology
techniques (prior to the 1980s), women suffering from PCS
were treated surgically with ovarian vein ligation or even
subjected to total hysterectomy [15].
The first ovarian vein embolization was performed by
Edwards in 1993 [16]. Since then, embolization has
become the first-line treatment of PCS due to its low
invasiveness and high efficacy [3–5, 17]. The findings of
many prospective studies have demonstrated the efficacy
up to 83 % of the procedure to be over 48 months without
adverse effects, such as returned pain, menstrual disorders,
disruption of the hormonal metabolism or reduced fertility
[18]. Various embolization techniques have been described
to occlude ovarian veins. The most often reported is the use
of pushable fibered 0.03500 coils advanced through normal
diagnostic catheters. The main drawback of this technique
is the need to use many coils, frequently along the whole
course of the vein. This is because one coil (or even few)
may not give immediate, complete occlusion, especially
when ovarian vein is dilated over 10 mm [5, 17, 18]. Thus,
authors emphasize the need for additional administration of
obliteration agents (i.e. 3 % polidocanol) [3, 4, 17]. There
are also some reports on using microcatheters and platinum
microcoils. Such procedures generally are considered more
advanced techniques and are more expensive, thus used in
more complex anatomy, when conventional techniques
have failed [5, 19].
What interested us in this study was the evaluatation of
the possible advantage of immediate ovarian vein occlu-
sion using the new occlusion device (ArtVentive EOSTM).
Materials and Methods
All patients with PCS were assessed for treatment by a
gynaecologist. After obtaining a medical history, each
patient underwent physical examination and TVUS fol-
lowed by an MRI study (FSE T2-weighted fat saturation
sequences and/or 3D volumetric protocol)—showing
ovarian vein dilatation and uterine plexus varicosity. None
of patients in our group was diagnosed with evident
Fig. 1 ArtVentive EOSTM schematic picture (A) and the occlusion
system preparation (B)—flushing of a PTFE coating of the device
(arrow) before placing it into introducing catheter
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coexisting vulvar venous reflux or lower limb varicosity.
All the data were then evaluated by an interventional
radiologist for possible embolization. The embolization
procedures were performed up to the tenth day of the cycle
after excluding pregnancy with a serum B-HCG test.
Additional laboratory tests included platelet count, clotting
time, blood urea nitrogen and creatinine.
A prospective observational study was performed in
June and July 2014—twelve patients were diagnosed with
PCS and scheduled for embolization. The pain intensity
was assessed before and 6 months after embolization using
visual analog scale (VAS)—from 0 to 10 (where 0 repre-
sents lack of pain and 10—unbearable pain). Before the
procedure, the mean VAS score was 7.3 (standard devia-
tion: 0.98). The age of patients ranged from 21 to 48 years
(34 average); 1 patient was nulliparous, 4—primiparous
and 7 were multiparous.
All embolization procedures were performed in the
interventional radiology laboratory using a DSA system
(Artis Zee, Siemens AG, Erlangen, Germany). In all cases,
we used the right common femoral vein access after a local
anaesthesia with 2 % lidocaine. A 7F vascular sheath was
placed, and initial venography of the left renal vein was
performed during Valsalva manoeuvre using a 5F Cobra II
catheter. On the right side, the catheter was positioned at
the right ovarian vein ostium. The ovarian veins were
catheterized using a hydrophilic guidewire (Glidewire,
Terumo Europe, Leuven, Belgium) and a 5F Cobra II on
the left side or a 5F Simmons I on the right side (William
Cook Europe, Bjaeverskov, Denmark). After successful
ovarian vein catheterization, an exchange length of 260-cm
Rosen exchange guidewire (William Cook Europe,
Bjaeverskov, Denmark) was placed, and over this wire, a
diagnostic catheter was exchanged for a guiding catheter.
We used 6F and 7F deployment catheters (ArtVentive
Medical, Carlsbad, CA, USA). After removing the guide-
wire and dilator from the deployment catheter, occluding
devices were delivered to the desired place in the ovarian
vein. The ArtVentive EOSTM is a spiral nitinol coil covered
with an ePTFE material. It is preloaded as a double-step
detachable system enabling predeployment position check,
possible repositioning and final deployment. It is available
in three sizes: dedicated for vessels 3.5–5, 4.5–8 and
7.5–11 mm in diameter. The first two sizes are compatible
with the 6F deployment catheter and the largest one
requires the 7Fr guiding catheter (Fig. 1). We used two
sizes of occluders—4.5–8 mm in 4 patients and
7.5–11 mm in 7 patients. Two–five occluding devices were
used in each patient—an average of two occluders per one
vessel were implanted: one as distally as possible in the
dilated ovarian vein trunk and the second 5–10 cm proxi-
mally. The size of each device was determined after the
target vessel measurement, and it was oversized approxi-
mately by 20 % in diameter to obtain better vein occlusion
and to reduce the risk of device migration.
Criteria used for unilateral (left) or bilateral emboliza-
tion included clinical pain location, as well as the imaging
of reverse flow through the dilated ovarian vein to the
parametrial plexus—TVUS/MR findings. The final deci-
sion was made during venography with a Valsalva
Fig. 2 The 22-year-old female with PCS. A The MR appearance of
the dilated left ovarian vein (arrowheads)—FSE T2-weighted
sequence with fat-sat (MIP reconstruction). B Initial venography,
showing a complex confluence of dilated ovarian vein. C The first
occlusion device on position—right over the lower, major veins
confluence (white arrow). D Check venography, after placement of
the second occluder, implanted over the highest venous confluence
(black arrow)
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manoeuvre. Nine women underwent unilateral emboliza-
tion of the left ovarian vein; in two cases, both right and
left ovarian veins were intended to be closed with the
ArtVentive EOSTM—but in one patient with an extremely
difficult access route (acute angulation with IVC)—the
right ovarian vein was then embolized using a micro-
catheter (Progreat, Terumo Europe, Leuven, Belgium)
and microcoils (ConcertoTM, Covidien, Dublin, Ireland).
These procedures lasted from 19 to 45 min (average
28)—a time reflecting the total duration of the treatment
from venous access to target vessel occlusion and intro-
ducer withdrawal. The mean fluoroscopy time was 13 min
(ranged from 10 to 23). We also noted the radiation dose
per procedure measured using a DSA system as the Ref-
erence Point Air Kerma—it was an average of 325 mGy
(ranging from 146 to 1619). An average of 55 ml of con-
trast medium was administered per procedure.
The technical success of embolization was defined as a
total occlusion of the targeted ovarian vein and no-flow of
the contrast medium on check venography, during the
Valsalva manoeuvre. The procedure effectiveness was
evaluated 3 months after embolization—based on a history
of residual pain intensity, physical examination and TVUS.
Results
Successful embolization procedure with ArtVentive
EOSTM was achieved in 11 out of 12 patients. In one
patient, we could not advance the 7F deployment catheter
to dilated left ovarian vein as it could not pass the proximal
valve. Thus, safe occluding device implantation was not
possible. The patient was then successfully treated using
pushable coils implanted through the 5F diagnostic catheter
which was placed distally in the ovarian vein after passing
the proximal valve. In addition, in one patient, after suc-
cessful left-sided ArtVentive EOSTM delivery, we were
unsuccessful in placing the 6F deployment catheter in the
dilated right ovarian vein. In this case, the embolization
procedure was completed using a microcatheter and plat-
inum microcoils.
Complete occlusion of the ovarian vein using the
ArtVentive EOSTM was achieved in 11 patients (Fig. 3),
including one patient embolized with the occluding device
only on the left side (as described above). Eight patients
were discharged from the hospital the same day as the
procedure. Four women had some periprocedural discom-
fort and reported as prolonged pain or discomfort in the
lower abdomen/pelvic region. This was resolved sponta-
neously before their discharge next morning.
A reduction in pelvic pain intensity assessed using VAS
was considered as clinical success and was observed in all
the patients - pain decreased by 5.63 points on average
(from 7.27 to 1.64 pts) in 6 months follow-up (Fig. 4).
There were no major device-related complications or
device malfunctions during delivery and deployment. In
one case, an ovarian vein was perforated by a guidewire
manipulation with the minimal contrast agent extravasation
being documented. This was not clinically significant, both
immediately after the procedure and during the follow-up.
Discussion
PCS has been reported to negatively affect quality of life
and personal relationships. It results in physical and psy-
chological disorders. The latter may lead to depression and
anxiety [1, 2]. Finally, pain related to PCS is frustrating
both for patients and treating physicians, especially when
the therapy fails [20]. It is also recognized that pelvic
varicosities are often found incidentally in asymptomatic
patients. According to available studies, pelvic varices
occur in 38–47 % of women without PCS symptoms
[1, 2, 18]. This means that only about 60 % of patients with
varicose ovarian veins have symptoms of chronic pelvic
pain syndrome and need treatment [1–3, 9]. Therefore, a
good cooperation between gynaecologists (offering clinical
assessment) and radiologists (providing appropriate imag-
ing to direct possible intervention) is desirable for proper
patients’ selection for treatment.
Contemporary scientific data show that the percuta-
neous, endovascular ovarian vein embolization is the cur-
rent standard procedure for PCS therapy with a technical
effectiveness estimated at 96–100 % and recurrence inci-
dence of 10–20 % [5, 19–21].
In the study by Laborda et al., a group of 202 patients
who underwent embolization for PCS were investigated.
The technical success was 100 %. In 68.3 % of patients, all
4 veins involved were closed; 3 veins were embolized in
23.8 % of patients and 2 veins in 7.9 % of patients. The
mean procedural time was 43.3 ± 6.9 min. Embolization
coils migrated in four cases (1.9 %). The coils were suc-
cessfully removed using endovascular loop shares in three
cases; in one case, the coil migrated to the lungs, and the
patient refused further treatment and remained asymp-
tomatic. No remote embolization-related complications
were observed after 5 years [21].
Nasser et al. reported that a substantial decrease in pain
over a 12-month period (from 7.34 to 0.47 according to
VAS) was noted, despite less frequent closure of internal
iliac veins, when compared to the study by Laborda et al.
(LIIV 91 vs. 80 %, RIIV 74 vs. 46 %). In this group of
13 patients, four complications were observed, i.e.
migration of coils, which were removed using endovas-
cular loops. No fatal procedure-related complications
were noted [22].
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Although limited by the relatively small number of
patients, our study showed promising results confirming
the safe and effective use of the new occlusion device in
the endovascular treatment of PCS. Technically, the new
occluder in all successful cases, was implanted very pre-
cisely with possibility to correct its initial position. In both
patients in whom we were not able to catheterize ovarian
vein (one of them the left one and the second on the right
site) with the deployment catheter using femoral access, it
would possibly be easier to do this with jugular access.
Many authors report that all the pelvic embolization pro-
cedures they perform are from jugular site. The jugular
access enables easier catheterization, especially, when
multi-vessel (ovarian and internal iliac veins) embolization
is performed [4, 5, 17]. In patients with only ovarian veins
embolization planned, the femoral access is in our opinion
good enough. Some interventionists also reported good
technical outcomes of glue embolization in PCS patients
[4, 5, 20]. We also use cyanoacrylate glue but mainly in
male varicoceles embolization, particularly when anatomy
of spermatic veins is difficult and the use of microcatheter
is needed. In females with PCS, the use of glue is, in our
opinion (confirmed by others), limited by ovarian vein
dilation exceeding 8–10 mm and higher possibility for
uncontrolled liquid embolic material migration [23].
In this study, we did not use any sclerosants because we
wanted to collect data of immediate, total ovarian vein
occlusion without the influence of other embolic/sclerosing
agents. But of course, it is possible to perform embolization
with combination of occluders and other agents.
Embolization performed by distal and proximal vein
occlusion with the additional use of obliteration agent
called ‘‘sandwich technique’’ is a valued technique. In
every technique, the aim is to embolize the whole length of
the vein. Decision concerning the selection of the most
effective technique should be appropriately tailored to the
specific clinical conditions.
Another observation from our study is that the use of the
occluding devices may shorten procedure times and reduce
radiation doses. This is very important, but it is rather an
issue in PCS patients diagnosed with only ovarian veins
Fig. 3 The 31-year-old female with PCS. A Initial venography,
diagnostic catheter placed down in the main dilated ovarian vein.
B Check venography, from introducing catheter. C The ArtVentive
EOSTM device on position. D Partially deployed occluder (position
correction possible). E The final venography after placement of the
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Fig. 4 Rating VAS scale of the reported pain—before and 6 months
after embolization
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and uterine plexus incompetence. In patients suffering from
PCS with more than one or two ovarian veins affected, the
use of many (more than 2–3) occluders is probably not
shorter than routine coiling and is not more cost effective.
The possible advantage of the use of complete occluding
systems with controlled deployment is to decrease number
of cases with non-target embolization (i.e. coils migra-
tions), due to ability of repositioning. In addition, we think
(according Venbrux) that immediate and total occlusion
may reduce the possible necessity for retreatment [24].
Finally, we report that, the clinical results at 6 months of
the use of the ArtVentive EOSTM are comparable to other
studies, not only in PSC patients with dominant ovarian
veins incompetence [3, 4, 18, 21, 22].
Conclusions
The use of ArtVentive EOSTM for occlusion of the ovarian
veins in PCS patients is safe and effective. All the occlu-
sion devices were implanted as planned with good
deployment control and possible correction of its initial
position. During the 6-month observation, reduction of
pelvic pain after ovarian veins embolization was substan-
tial—from 7.27 to 1.64 according to VAS.
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